Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 701–800 of 1,000
Chawla, S., Hill, A., Fearfield, L. A., Johnston, S. R. D., Parton, M., & Heelan, K. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06169-9 · Cited by 21
Hamilton, E. P., Patel, M. R., Borges, V. F., Meisel, J. L., Okera, M., Alemany, C. A., Pluard, T., Wesolowski, R., Sabanathan, D., Miller, K. D., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02049-y · Cited by 21
Zhang, Q., Shao, Z., Shen, K., Li, L., Feng, J., Tong, Z., Gu, K., Wang, X., Xu, B., Sun, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10254 · Cited by 21
Wang, H., Liao, P., Zeng, S. X., & Lu, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685289 · Cited by 21
“Food and Drug Administration (FDA) for breast cancer treatment.(25,26) Also, PD shows tolerable toxicity and is predicted to be effective in other tumor types, such as HCC that often harbors an intact Rb.”
BackgroundClinical application of circulating tumor DNA in breast cancer
Chan, J. C. H., Chow, J. C. H., Ho, C. H. M., Tsui, T. Y. M., & Cho, W. C. S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03588-5 · Cited by 21
Dowsett, M., Kilburn, L., Rimawi, M. F., Osborne, C. K., Pogue-Geile, K., Liu, Y., Jacobs, S. A., Finnigan, M., Puhalla, S., Dodson, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1628 · Cited by 21
Self-citationColonic Metastasis from Breast Cancer: A Case Report and Review of the Literature
Inoue, H., Arita, T., Kuriu, Y., Shimizu, H., Kiuchi, J., Yamamoto, Y., Konishi, H., Morimura, R., Shiozaki, A., Ikoma, H., et al. (2021) · In Vivo · doi:10.21873/invivo.12733 · Cited by 20
Endocrine resistant breast cancer: brain metastasis
Willman, M., Willman, J., & Lucke-Wold, B. P. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00081 · Cited by 20
Breast Cancer Genomics: Primary and Most Common Metastases
Bennett, C., Carroll, C., Wright, C., Awad, B., Park, J. M., Farmer, M. B., Brown, E. (., Heatherly, A., & Woodard, S. A. (2022) · Cancers · doi:10.3390/cancers14133046 · Cited by 22
Wang, S., Bei, Y., Tian, Q., He, J., Wang, R., Wang, Q., Sun, L., Ke, J.-Q., Xie, C., & Shen, P. (2022) · Cell Proliferation · doi:10.1111/cpr.13337 · Cited by 21
Kawai, M., Takada, M., Nakayama, T., Masuda, N., Shiheido, H., Cai, Z., Huang, Y., Kawaguchi, T., & Tanizawa, Y. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06816-9 · Cited by 20
Clark, A. S., Hong, F., Finn, R. S., DeMichele, A. M., Mitchell, E. P., Zwiebel, J. A., Arnaldez, F. I., Gray, R. J., Wang, V., McShane, L. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2150 · Cited by 22
Hopcroft, L., Wigmore, E. M., Williamson, S. C., R�os, S., Eberlein, C., Moss, J. I., Urosevic, J., Carnevalli, L. S., Talbot, S., Bradshaw, L., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00571-w · Cited by 23
Senescence program and its reprogramming in pancreatic premalignancy
Yang, K., Li, X., & Xie, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06040-3 · Cited by 21
Lo, Y.-C., & Lin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102429 · Cited by 21
“PBC was approved for the treatment of ER+/HER2- breast cancer in US [4].”
MethodTargeted adjuvant therapy in breast cancer
Zardavas, D., Tryfonidis, K., Goulioti, T., & Piccart, M. J. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1247698 · Cited by 23
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035)
Tartari, F., Santoni, M., Pistelli, M., & Berardi, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.005 · Cited by 20
Li, Y., Wang, X.-M., Qiao, G., Zhang, S., Wang, J., Cong, Y., & Zhu, S. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.040 · Cited by 20
Mull, B. B., Livingston, J. A., Patel, N. B., Bui, T. N., Hunt, K. K., & Keyomarsi, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0707-z · Cited by 21
Odan, N., Kikawa, Y., Matsumoto, H., Minohata, J., Suwa, H., Hashimoto, T., Okuno, T., Miyashita, M., Saito, M., Yamagami, K., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420983843 · Cited by 22
Habler, K., Kalla, A.-S., Rychlik, M., Vogeser, M., & Teupser, D. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115211 · Cited by 22
Specialty pharmacy services for patients receiving oral medications for solid tumors
Stein, J., & Mann, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150863 · Cited by 21
Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer
Sutherland, S., Miles, D., & Makris, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.019 · Cited by 20
He, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 24
Heilmann, T., Dittmann, L., van Mackelenbergh, M., Mundhenke, C., Weimer, J. P., Arnold, N., Maass, N., & Schem, C. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4104-z · Cited by 19
Apostolidou, K., Zografos, E., Papatheodoridi, A. M., Fiste, O., Dimopoulos, M. A., & Zagouri, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103729 · Cited by 20
“The phase III study PALOMA-3 showed that combination treatment with palbociclib plus fulvestrant was associated with significant improvements in PFS compared to fulvestrant plus placebo in patients with metastatic breast cancer that had progressed during prior ET [36].”
BackgroundCDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 20
Zhang, Y., Liu, C., Yang, Y., Ren, H., Ren, T., Huang, Y., Zhang, S., Sun, Q., & Huang, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02152-7 · Cited by 20
Does CDKN2A Loss Predict Palbociclib Benefit?
Gao, J. J., Adams, R. P., & Swain, S. M. (2015) · Current Oncology · doi:10.3747/co.22.2700 · Cited by 19
Kessler, L. E., Wiklander, O. P. B., Hamberg, E., Bergh, J. C. S., Foukakis, T., & Matikas, A. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1804613 · Cited by 20
Li, Y., Li, L., Du, Q., Li, Y., Yang, H., & Li, Q. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1910705 · Cited by 19
Iuliani, M., Simonetti, S., Ribelli, G., Napolitano, A., Longo, U. G., Vincenzi, B., Orsaria, P., Denaro, V., Tonini, G., Santini, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052477 · Cited by 19
Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes
Zhao, B., & Pritchard, J. R. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006081 · Cited by 21
Bashour, S. I., Doostan, I., Keyomarsi, K., Valero, V., Ueno, N. T., Brown, P. H., Litton, J. K., Koenig, K. B., Karuturi, M. S., Abouharb, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.18196 · Cited by 19
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer
Flaum, L., & Gradishar, W. J. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_9 · Cited by 19
Androgen blockade based clinical trials landscape in triple negative breast cancer
Shi, Y., Yang, F., Huang, D., & Guan, X. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.004 · Cited by 20
Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
Uras, I. Z., Maurer, B., Nebenfuehr, S., Zojer, M., Valent, P., & Sexl, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123987 · Cited by 20
“cancer [39,40] and is being clinically evaluated in other cancers.”
BackgroundOceguera-Basurto, P. E., Topete, A., Oceguera‐Villanueva, A., Rivas‐Carrillo, J. D., Paz-Davalos, M., Ramos, A. Q., Toro‐Arreola, A. D., & Daneri‐Navarro, A. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-1956 · Cited by 19
Beusterien, K. M., Maculaitis, M. C., Hallissey, B., Gaschler, M. M., Smith, M. L., & Law, E. H. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s298670 · Cited by 20
Lee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 19
Tóth, F., Moftakhar, Z., Sotgia, F., & Lisanti, M. P. (2024) · Cells · doi:10.3390/cells13100841 · Cited by 19
Murad, B., Reis, P. C. A., Marinho, A. D., Comini, A. C. M., Xavier, D. P., Pessoa, B., Raheem, F., Ernst, B. J., Mina, L. A., & Batalini, F. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae078 · Cited by 22
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18
Metastatic breast cancer: The Odyssey of personalization
Sonnenblick, A., Ponde, N. F., & Piccart, M. J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.002 · Cited by 20
Boér, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s77033 · Cited by 19
How may targeted proteomics complement genomic data in breast cancer?
Guérin, M., Gonçalvès, A., Toiron, Y., Baudelet, É., Audebert, S., Boyer, J.-B., Borg, J., & Camoin, L. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1256776 · Cited by 19
Palbociclib: A new hope in the treatment of breast cancer
Palanisamy, R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.168988 · Cited by 19
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
Tanaka, T., Terai, Y., Ashihara, K., Fujiwara, S., Tanaka, Y., Sasaki, H., Tsunetoh, S., & Ohmichi, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177019 · Cited by 19
Gopalakrishnan, V., Tan, C. R., & Li, S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1312235 · Cited by 19
Dalal, A. A., Gagnon‐Sanschagrin, P., Burne, R. M., Guérin, A., Gauthier, G., Small, T., & Niravath, P. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0701-5 · Cited by 19
Palbociclib—The First of a New Class of Cell Cycle Inhibitors
Schmidt, M., & Sebastian, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_11 · Cited by 21
Identification of potentially druggable molecular alterations in skin adnexal malignancies
Cavalieri, S., Busico, A., Capone, I., Conca, E., Dallera, E., Quattrone, P., Licitra, L. F., Pruneri, G., Bossi, P., & Perrone, F. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14889 · Cited by 18
Scheinberg, T., Kench, J. G., Stockler, M. R., Mahon, K. L., Sebastian, L. T., Stricker, P. D., Joshua, A. M., Woo, H. H., Thanigasalam, R., Ahmadi, N., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033667 · Cited by 18
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
Takahashi, M., Masuda, N., Nishimura, R., Inoue, K., Ohno, S., Iwata, H., Hashigaki, S., Muramatsu, Y., Umeyama, Y., & Toi, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3091 · Cited by 19
Self-citationEverolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
Raphael, J., Lefebvre, C., Allan, A. L., Helou, J. A., Boldt, G., Vandenberg, T. A., & Blanchette, P. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00770-6 · Cited by 18
Løkkegaard, S., Eliáš, D., Alves, C. L., Bennetzen, M. V., Lænkholm, A., Bak, M., Gjerstorff, M. F., Johansen, L. E., Vever, H., Bjerre, C. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00210-8 · Cited by 20
Shikanai, A., Horimoto, Y., Ishizuka, Y., Uomori, T., Nakai, K., Arakawa, A., & Saito, M. (2022) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211065148 · Cited by 19
Wan, X., Zhang, Y., Ma, J., Tan, C., Zeng, X., & Peng, L. (2018) · The Breast · doi:10.1016/j.breast.2018.10.004 · Cited by 18
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
Masuda, N., Mukai, H., Inoue, K., Rai, Y., Ohno, S., Mori, Y., Hashigaki, S., Muramatsu, Y., Umeyama, Y., Iwata, H., et al. (2019) · Breast Cancer · doi:10.1007/s12282-019-00970-7 · Cited by 21
Self-citationHart, L. L., Im, S., Tolaney, S. M., Campone, M., Pluard, T., Sousa, B., Freyer, G., Decker, T., Kalinsky, K. M., Sopher, G. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115225 · Cited by 17
Kwapisz, D. M. (2018) · Breast Cancer · doi:10.1007/s12282-018-0864-6 · Cited by 18
Yoshinami, T., Nagai, S. E., Hattori, M., Okamura, T., Watanabe, K., Nakayama, T., Masuda, H., Tsuneizumi, M., Takabatake, D., Harao, M., et al. (2024) · Breast Cancer · doi:10.1007/s12282-024-01575-5 · Cited by 21
Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Walker, R. L., Hornicek, F. J., & Duan, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116342 · Cited by 18
Ahn, H. K., Kim, J., Lee, K.-H., Kim, G. M., Kang, S. Y., Lee, K. S., Kim, J. H., Lee, K. E., Lee, M. H., Kim, H. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00006-3 · Cited by 22
Ban, M., Miše, B. P., Majić, A., Dražić, I., & Vrdoljak, E. (2017) · Future Oncology · doi:10.2217/fon-2017-0491 · Cited by 17
Guo, Q., Lin, X., Ye, L., Xu, R., Dai, Y., Zhang, Y., & Chen, Q. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00633-9 · Cited by 17
Mayer, E. L., DeMichele, A. M., Rugo, H. S., Miller, K. D., Waks, A. G., Come, S., Mulvey, T. M., Jeselsohn, R. M., Overmoyer, B. A., Guo, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz198 · Cited by 17
Self-citationDasgupta, A., Sahgal, A., Warner, E., & Czarnota, G. J. (2020) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.435 · Cited by 17
Sun, J. X., Zhong, X., Ma, J., Sun, W., Han, H. S., Soliman, H. H., Loftus, L., Costa, R. L. B., Armaghani, A. J., Soyano‐Muller, A. E., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4295 · Cited by 17
Kim, J., Oh, J. M., Park, Y. H., Ahn, J. S., & Im, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759150 · Cited by 18
Law, J. W., Mitra, D., Kaplan, H. G., Alfred, T., Brufsky, A., Emir, B., McCracken, H., Liu, X., Broome, R. G., Zhang, C., et al. (2022) · Current Oncology · doi:10.3390/curroncol29020089 · Cited by 17
Chen, W., Zhang, W., Chen, M., Yang, C., Fang, T., Wang, H., Reid, L. M., & He, Z. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00714-4 · Cited by 17
microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network
Zhou, Y., Frings, O., Branca, R. M., Boekel, J., le Sage, C., Fredlund, E., Agami, R., & Orre, L. M. (2016) · Oncogene · doi:10.1038/onc.2016.242 · Cited by 18
Negasa, D. E., & Sisay, M. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s150540 · Cited by 17
Long, Q., Ma, A., Zhang, H., Cao, Z., Xia, R., Lin, T., Sonpavde, G., White, R. D., Guo, J., & Pan, C.-X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02609-5 · Cited by 18
Chen, F., Zhang, Z., Yu, Y., Liu, Q., & Pu, F. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5057 · Cited by 17
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_9 · Cited by 19
Chen, M., Chen, W., Sun, S., Lu, Y., Wu, G., Xu, H., Yang, H., Li, C., He, W., Xu, M., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.08.034 · Cited by 17
“The US Food and Drug Administration (FDA) has approved PD-0332991 for the clinical treatment of advanced ER + HER2 - breast cancer [17,18].”
Current views on inducing synthetic lethal RNAi responses in the treatment of cancer
Kacsinta, A. D., & Dowdy, S. F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1110141 · Cited by 18
Profile of palbociclib in the treatment of metastatic breast cancer
Elbaz, M., & Ehab, M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s83146 · Cited by 22
Palumbo, R., Sottotetti, F., Quaquarini, E., Gambaro, A., Ferzi, A., Tagliaferri, B., Teragni, C. M., Licata, L., Serra, F., Lapidari, P., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833864 · Cited by 18
Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Schütz, F., Fasching, P. A., Kolberg, H., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1039-4458 · Cited by 17
Nakatani, K., Matsuo, H., Harata, Y., Higashitani, M., Koyama, A., Noura, M., Nishinaka‐Arai, Y., Kamikubo, Y., & Adachi, S. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03015-4 · Cited by 19
Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association
Marcianò, A., Guzzo, G. M., Peditto, M., Picone, A., & Oteri, G. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249509 · Cited by 19
Servetto, A., Napolitano, F., Angelis, C. D., Placido, P. D., Giuliano, M., Arpino, G., Placido, S. D., Bianco, R., & Formisano, L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103191 · Cited by 18
“ctDNA samples from patients enrolled in the PALOMA-3 trial [4], the landscape of the genomic alterations associated with resistance to fulvestrant plus palbociclib.”
BackgroundRugo, H. S., Haltner, A., Zhan, L., Tran, A., Bananis, E., Hooper, B., Mitra, D., & Cameron, C. G. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0272 · Cited by 16
Agrawal, C. R., Goyal, P., Agarwal, A., Tripathi, R., Dodagoudar, C., Baghmar, S., Sharma, A. K., Batra, U., Talwar, V., Goyal, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95758-1 · Cited by 18
Ateş‐Alagöz, Z., Kışla, M. M., Karadayı, F. Z., Baran, S., Doğan, T. S., & Mutlu, P. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02808a · Cited by 16
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
Duranti, S., Fabi, A., Filetti, M., Falcone, R., Lombardi, P., Daniele, G., Franceschini, G., Carbognin, L., Palazzo, A., Garganese, G., et al. (2021) · Cancers · doi:10.3390/cancers13205198 · Cited by 18
Vinciguerra, G. L. R., Dall’Acqua, A., Segatto, I., Mattevi, M. C., Russo, F., Favero, A., Cirombella, R., Mungo, G., Viotto, D., Karimbayli, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04241-2 · Cited by 16
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
Shagisultanova, E. I., Crump, L. S., Borakove, M., Hall, J., Rasti, A. R., Harrison, B. A., Kabos, P., Lyons, T. R., & Borges, V. F. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0098 · Cited by 17
Wang, J., Xu, B., Wang, W., Zhai, X., & Chen, X. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4867-y · Cited by 16
Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer.
Han, B. S., Jung, K. H., Lee, J. E., Yoon, Y., Ko, S., Park, M. S., Lee, Y. J., Kim, S. E., Cho, Y. J., Lee, P., et al. (2022) · PubMed · Cited by 16
Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
Helbig, D., & Klein, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975342 · Cited by 17
Zoghi, B., & Elledge, R. M. (2016) · The Breast Journal · doi:10.1111/tbj.12554 · Cited by 16
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
Ding, W., Li, Z., Wang, C., Ruan, G., Chen, L., & Tu, C. (2018) · Medicine · doi:10.1097/md.0000000000010746 · Cited by 18
Riccardi, F., Colantuoni, G., Diana, A., Mocerino, C., Carten�, G., Lauria, R., Febbraro, A., Nuzzo, F., Addeo, R., Marano, O., et al. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1672 · Cited by 22
Böhm, M., Marienfeld, R. B., Jäger, D., Mellert, K., Witzleben, A. V., Brüderlein, S., Wittau, M., von Baer, A., Schultheiß, M., Mayer‐Steinacker, R., et al. (2019) · Sarcoma · doi:10.1155/2019/3914232 · Cited by 20
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.